1201 New York Avenue, NW., Suite 500
Washington, DC 20005-3917

September 5, 1997

The Honorable William V. Roth, Jr.
Chairman
Committee on Finance
United States Senate
Washington, DC 20510-6200
Dear Mr. Chairman:
In accordance with the Ethics in Government Act of 1978, I enclose a copy of the financial disclosure report filed by Margaret A. Hamburg, who has been nominated by President Clinton for the position of Assistant Secretary for Planning and Evaluation, Department of Health and Human Services.

We have reviewed the report and have also obtained advice from the Department of Health and Human Services concerning any possible conflict in light of its functions and the nominee's proposed duties. Also enclosed is a letter dated September 3. 1997, from the Department's ethics official, outlining the steps which Ms. Hamburg will take to avoid conflicts of interest. Unless a specific date has been agreed to, the nominee must fully comply, within three months of her confirmation date, with the actions she agreed to take in her ethics agreement.

Based thereon, we believe that Ms. Hamburg is in compliance with applicable laws and regulations governing conflicts of interest.

Sincerely,
 Director

Enclosures

United States
Office of Government Ethics
1201 New York Avenue, NW., Suite 500
Washington, DC 20005-3917

January 20, 1998

Edgar M. Swindell
Acting Associate General Counsel for Ethics and
Designated Agency Ethics Official
Department of Health and Human Services
700-E Humphrey Building
200 Independence Avenue, SW.
Washington, DC 2020.
Dear Mr. Swindell:
I am writing to you concerning the ethics agreements made by Presidential appointees to positions requiring the advice and consent of the Senate pursuant to 5 U.S.C. App. 6 § 110. Upon confirmation, an appointee has three months (unless otherwise specified by the agreement) in which to satisfy any ethics agreement.

An appointee must notify his or her designated agency ethics official (DAEO), of any action(s) taken to satisfy his/her ethics agreement. Once the DAEO has received verification of compliance, he or she must submit this documentation to the Office of Government Ethics (OGE) and the appropriate Senate confirmation committee (See 5 C.F.R. § 2634.804).

In order to assist you in doing timely follow-ups on ethics agreement compliance, OGE has adopted the practice of formally contacting agencies, in writing, to remind them of outstanding (i.e., unsatisfied, but not yet delinquent) ethics agreements. OGE will forward its first letter approximately 45 days after the appointee's confirmation date. If the ethics agreement remains outstanding, a second letter will be sent approximately 85 days after the confirmation date, when the three-month time limit is about to expire. Hopefully, these formal reminders will reduce the number of ethics agreements that actually reach the delinquent stage.

Presently, two Department of Health and Human Services appointees have outstanding ethics agreements. Below are the names of those appointees, their confirmation dates, and as of January 12, 1998, the number of days since their confirmation.

## Appointees

Hamburg, Margaret A.
Takamura, Jeanette C.

Confirmation Date
October 30, 1997
November 6, 199767

74
Days Since
Confirmation

Mr. Edgar M. Swindell
Page 2
Your attention to this matter is appreciated. If you should have any problems or questions, please contact Ms. Grace Clark at 202-208-8000, ext. 1170.

Sincerely,
Jack Covaleski
Senior Associate Director Office of Agency Programs
GC/gc(sh)
ETH-7-3
278 Folders
Read File

United States
Office of Government Ethics


June 5, 2001

Edgar M Swindell
Associate General Counsel Ethics and
Designated Agency Ethics Official
Department of Health and
Human Services
700-E Humphrey Building
200 Independence Avenue, SW.
Washington, DC 20201
Dear Mr Swindell:
I am writing to ask that you provide us with the 1999 and 2000 annual and termination public financıal disclosure reports (SF 278) for several employees of the Department of Health and Human Services. As yet, we have not received reports from the enclosed lıst of indıviduals.

One of the objectives of the Financial Disclosure Division is to put increased emphasis on the timely submission of annual and termination financial disclosure reports for Presidential appointees confirmed by the Senate (PAS), and Designated Agency Ethics Officıals (DAEO)

We have previously asked that each DAEO (OGE DAEOgram, D0-00-018, dated May 10, 2000) inform us no later than September 15, 2000 of instances where a report could not be approved by the agency and submitted to this Office, due to pending resolution of a conflict of interest, or the need for additional information or clarification. Moreover, we recently contacted the agencies to help determine the status of the outstanding reports. While we have been able to obtain the status on many of these reports, we still require your assistance to complete this task.

Please forward the reports or provide us with information regarding problems you are having in collecting, reviewing or correcting the reports. Your cooperation in this matter is greatly apprecıated If you have any questions, please contact Teresa Weakley of my staff, at (202) 208-8000, extension 1233. Her e-mall address is tlweakle@oge.gov.

Sincerely,

Enclosure

```
T. Weakley/TW(vm)
ETH 5-5
ETH 7-3
SF 278 File
```


## 1999 Annual SF 278

Margaret A Hamburg
Rıchard J. Tarplin

## 2000 Annual SF 278

Margaret A. Hamburg
Harriet S. Rabb
Rıchard J. Tarplin

2000 Termination SF 278
Nelba R. Chavez

United States
Office of Government Ethics
1201 New York Avenue, NW., Suite 500
Washington, DC 20005-3917
March 12, 2002

Edgar M. Swindell
Associate General Counsel Ethics and Designated Agency Ethics Official
Department of Health and
Human Services
700-E Humphrey Building
200 Independence Avenue, SW.
Washington, DC 20201
Dear Mr. Swindell:
I am writing to ask that you provide us with the 2001 termination public financial disclosure reports. (SF 278) for several employees of the Department of Health and Human Services. As yet, we have not received reports from the enclosed list of individuals.

We have previously asked that each DAEO (OGE DAEOgram, DO-01-019, dated May 15, 2001) inform us no later than September 15, 2001 of instances where a report could not be approved by the agency and submitted to this Office, due to pending resolution of a conflict of interest, or the need for additional information or clarification. Moreover, we recently contacted the agencies to help determine the status of the outstanding reports. While we have been able to obtain the status on many of these reports, we still require your assistance to complete this task.

In addition, by letter dated June 5, 2001, we asked for the 1999 and 2000 annual $S F 278 \mathrm{~s}$ for Ms. Margaret A. Hamburg and Mr. Richard J. Tarplin. To date, we have not received the reports.

Please forward the reports as soon as possible or provide us with information regarding problems you are having in collecting, reviewing or correcting the reports. Your cooperation in this matter is greatly appreciated. If you have any questions, please contact Teresa Weakley of my staff, at (202) 208-8000, extension 1233. Her e-mail address is tiweakle@oge.gov.
T. Weakley/TW(vm)

ETH 5-5.1
ETH 7-3
Ed Pratt
D. Williams

Read File .,


Unıted States
Office of Government Ethics
1201 New York Avenue, NW., Surte 500
Washington, DC 20005-3917

Apcll 17, 2009

The Honorable Edward M Kennedy<br>Charrman<br>Committee on Health, Education,<br>Labor, and Pensions<br>United States Senate<br>Washington, DC 20510-6300<br>\section*{Dear Mr Charrman}

In accordance with the Ethics in Government Act of 1978, I enclose a copy of the financial disclosure report filed by Margaret A Hamburg, who has been nomınated by President Obama for the position of Commıssioner, Food and Drug Admınıstration, Department of Health and Human Services

We have reviewed the report and have also obtained advice from the Department of Health and Human Services concerning any possible conflict in light of its functions and the nominee's proposed duties Also enclosed is a letter dated March 26, 2009, from Dr Hamburg to the agency's ethics official, outlining the steps Dr Hamburg will take to avord conflicts of interest Unless a specific date has been agreed to, the nominee must fully comply within three months of her confirmation date with any action she agreed to take in her ethics agreement

Based thereon, we believe that Dr. Hamburg is in compliance with applicable laws and regulations governing conflicts of interest


Robert I Cusick
Director
LSyme/ts(r])
Hartourg 278
Read File

United States
Office of Government Ethics
1201 New York Avenue, NW., Suite 500
Washington, DC 20005-3917
July 2, 2009
Edgar Swindell
Associate General Counsel
Department of Health and Human Services
700-E Humphrey Building
200 Independence Avenue, SW.
Washington, DC 20201
Dear Mr. Swindell:
This letter concerns ethics agreements made by Presidential appointees to positions requiring the advice and consent of the Senate, pursuant to 5 U.S.C. App. 110. Upon confirmation, an appointee has 90 days (unless otherwise specified by the agreement) in which to satisfy any ethics agreement.

An appointee must notify her designated agency ethịcs official (DAEO) of any action(s) taken to satisfy her ethics agreement. Once the DAEO has received verification of compliance, he must submit this documentation to the Office of Government Ethics (OGE) and the appropriate Senate confirmation committee. (See 5 C.F.R. 2634.804.)

To assist agencies in ensuring that appointees comply with their ethics agreements within 90 days, I am writing to remind you that the following appointee has made an ethics agreement. As of July 2, 2009, she has 45 days remaining to comply with her ethics agreement.

## Appointee <br> Confirmation Date <br> Hamburg, Margaret <br> May 18, 2009 <br> August 16, 2009

If she has already complied, please collect the documentation and forward it to OGE. Should you have any questions or require additional assistance, such as obtaining a Certificate of Divestiture for an appointee, please do not hesitate to contact me at 202-282-9309 or khkaplan@oge.gov.

K. Kaplan/kk(vm)

ETH 5-7
ETH 7-3

United States
Office of Government Ethics
1201 New York Avenue, NW., Suite 500
Washington, DC 20005-3917

August 5, 2009

Edgar Swindell
Associate General Counsel/Ethics
Department of Health and Human Services
700-E Humphrey Building
200 Independence Avenue, SW.
Washington, DC 20201
Dear Mr. Swindell:
This is to follow up on the first reminder letter your agency received from OGE regarding recent political appointees with ethics agreements.

Within the next 11 days, the following appointee's time period to comply with her ethics agreement will expire. Please ensure that the appointee has satisfied the elements of her ethics agreement by $8 / 16 / 2009$ and notify OGE by this date about the status of compliance. All compliance documentation should be forwarded to OGE no later than 8/19/2009.



July 13, 2011

Ms Carol D Leonnig
Washington Post


## Tracking No OGE FOIA FY 11/62

Dear Ms Leonng
This is in response to your request for copies of "All ethics agreements entered into since January 2009 for PAS filers per attached hst" Your request was made on the OGE Form 201, Request to Inspect or Receive Copies of OGE Form 278/SF 278 Executive Branch Personnel Publıc Financial Disclosure Reports or Other Covered Records, but your request did not attach a list However, you indicated in a'telephone conversation with an Office of Government Ethics (OGE) staff member that you would like copies of the ethics agreements for the Presidentially-appointed and Senate confirmed (PAS) officials listed on the OGE website as of the date we received your request Your request, which was dated June 30, 2011, was received by OGE on July 5, 2011 Please note that because the Ethics in Government Act of 1978, as amended does not provide for the public release of the ethics agreements, your request is being processed under the Freedom of Information Act (FOIA), 5 U S C § 552

As a partial response to your request, we are releasing the ethics agreements of the individuals listed below We are continuing to process your request as to the remainder of the ethics agreements

Abbott, Sherburne B
Adelstein, Jonathon
Ah, Russlyn H
Allison, Herbert M
Appel, Peter H
Avant, Nicole A
Babbitt, Jerome R
Baker, Meredith
Baker, Roger W
Barr, Michael S
Beers, Rand
Benjamin, Daniel
Berry, M John
Berwick, Donald M

Beyer, Jr , Donald S
Blarr, Dennis C
Blake, Robert
Blanchard, Charles
Blank, Rebecca
Bleıch, Jeffrey L
Borzı, Phyllis
Bostic, Raphael
Boyd, April S
Brainard, Lael
Breuer, Lanny A
Brimmer, Esther D
Brınkman, William F
Bryson, John E
Burk, Susan F
C deBaca, Lurs E
Campbell, Kurt
Cannon, Jonathan Z
Carden, David L
Carson, Johnnie
Carter, Ashton B
Castle, Anne J
Chopra, Aneesh
Chu, Steven
Clinton, Hillary Rodham
Clyburn, Mignon
Cohen, David S
Concannon, Kevın
Connor, Michael L
Corr, William V
Crowley, Phulip J
Cunnıngham, Peter $P$
Daalder, Ivo H
Darcy, Jo-Ellen
Daschle. Thomas A
DePass, Michelle
Donahoe, Eileen C
Donovan, Shaun L S
Duckworth, Ladda T
Duncan, Arne S
Eacho, III, Willam Carlton
Easton, John Q
Echo Hawk, Larry J
Eikenberry, Karl W
Eisen, Norman L
Feltman, Jeffery D

Ms Carol D Leonnig<br>Page 3<br>Flournoy, Michele A<br>Fong, Ivan K<br>Fugate, Wilham C<br>Gallagher, Daniel M<br>Geithner, Timothy F<br>Genachowskı, Juhus M<br>Gensler, Gary<br>Gıles, Cynthia J<br>Gips, Donald<br>Goldsteın, Jeffrey A<br>Gomez, Gabriella<br>Goolsbee, Austan<br>Goosby, Eric<br>Gordon, Philip H<br>Gottenmoeller, Rose E<br>Gould, William Scott<br>Greenlee, Kathy<br>Gregson, Wallace C<br>Gresham, Dana G<br>Groves, Robert<br>Gunn, William<br>Guthrie, Priscilla<br>Gutman, Howard W<br>Hale, Robert F<br>Hamburg, Margaret<br>Harden, Krysta<br>Harris, Scott<br>Harrs, Seth D<br>Hayes, David W<br>Henrıquz, Sandra<br>Heyman, David<br>Hill, Christoper R<br>Hochberg, Fred<br>Holder, Eric H, Jr<br>Holdren, John P<br>Hudson, James L<br>Huntsman, Jon M. Jr<br>Jackson, Lisa P<br>Jenkıns, Bonnie<br>Johnsen, Dawn E<br>Johnson, Jeh C<br>Johnson, Krıstına M<br>Johnson, Martha N<br>Kagan, Elena<br>Kanovsky, Helen R<br>Kanter, Martha J

Ms Carol D Leonnıg
Page 4
Kaplan, Samuel L
Katz, Allan J
Kennard, William E
Kennedy. Brian V
Kerlikowske, Richard G
Kerr, Thomas Michael
Kerry, Cameron
Kienitz. Roy W
Kıng. Elizabeth
Kırk, RonaldKoh, Harold HKoh, Howard
Koonin, Steven E
Kovar, Peter A
Krıs, David S
Krueger. Alan B
LaHood, Raymond H
Lamont, Thomas
Lane, Jeffrey A
Leonard, Joe E
Lew, Jacob J
Lewis, Wilma A
Litt, Robert
Locke, Gary F
Lour, Patricia M
Lubchenco, Jane A
Lute, Jane H
Lynn, William J
Mabus, Raymond Jr
Madison, George
Manning, Timothy W
Marantis, Demetrios J
Marquez, Mercedes
Marshall, Capricia
Martın, Carmel
McCarthy, Regina
McDowell, Robert
McHale, Judith
McLellan, Thomas
Mendez, Victor
Merrıgan, Kathleen A
Miller, Anthony
Miller, James N, Jr
Miller, James W
Mills, Karen Gordon
Morin, Jamie
Ms Carol D Leonnıg
Page 5
Morton, John T
Nabors, Robert L II
Nacht, Michael
Napolitano, Janet A
Nazarıo, Carmen
Newell, Rıchard
Oates, Jane
Ogden, David W
Oreck, Bruch J
Orszag, Peter R
O'Toole, Tara
Owens, Stephen
Panetta, Leon E
Perez, Thomas E
Perrell, Thomas J
Petraeus, David H
Poneman, Daniel
Porcar1, John
Preston, Stephen
Rediker, Douglas A
Reed, Pearlıe
Remy, Donald
Ruce, Susan E
Rios, Rosa
Rıvkin, Charles
Robinson, Larry
Rogers, Thomasina
Rogoff, Peter
Romer, Christına D
Roos, John V
Rose, Charles P
Roubideaux, Yvette D
Rouse, Cecilia E
Salazar, Kenneth L
Sanchez, Francisco
Sandalow, David
Sapıro, Mırıam
Schapiro, Mary L
Schwartz, Eric P
Sebelius, Kathleen G
Sepulveda, John U
Shah, Rajeev
Shapiro, Andrew
Shinsekı, Enic K
Silva, Peter
Sıms, Ronald C

Ms Carol D Leonnig<br>Page 6<br>Smith, M Patricia<br>Smith, Mary L<br>Solis, Hilda L<br>Solomont, Alan D<br>Stanslaus, Marthy<br>Steınberg, James B<br>Stevens, David<br>Stockton, Paul<br>Strickland, Thomas L<br>Strickling, Lawrence E<br>Stroum, Cynthia<br>Suh, Rhea<br>Sullivan, John<br>Sunstein, Cass<br>Susman, Lours B<br>Sutley, Nancy H<br>Szabo, Joseph C<br>Tarullo, Danel K<br>Tauscher, Ellen<br>Tompkins, Hulary C<br>Tonsager, Dallas P<br>Trasvina, John<br>Triay, Ines R<br>Varney, Christıne A<br>Verma, Rıchard R<br>Vershbow, Alexander R<br>Verveer, Melanne S<br>Vilsack, Thomas J.<br>Wallace, Kım N<br>Weber, Andrew<br>Weich, Ronald H<br>Welters, Beatrice W<br>West, Derek A<br>White, Barry B<br>Wilkins, Willam<br>Wolin, Neal<br>Work, Robert<br>Zıents, Jeffrey<br>Zoı, Catherıne

These documents are being provided in their entirety, subject to various deletions, which are marked on the enclosed copies The deleted material, on approximately 40 pages, is being withheld under FOIA Exemptıons 4 and 6, 5 U S C $\S \S 552(\mathrm{~b})(4)$ and (b)(6) as commercial or financial information obtained from a person and privileged or confidential and information the disclosure of which would constitute a clearly unwarranted invasion of personal privacy

The OGE official responsible for this FOIA determination is the undersigned In accordance with the FOIA, as codified at 5 US C §552(a)(6)(A), and OGE's FOIA regulations, at 5 C F R $\S 2604304$, you may administratively appeal this partial denial of your request The name and address of the OGE official to whom such an appeal would have to be submitted are Don W Fox, General Counsel, Office of Government Ethics, Suite 500, 1201 New York Avenue, NW, Washington. DC 20005-3917 Any such appeal must be in writing and must be sent within 30 days of the date you receive this response letter If you do appeal, you should include copies of your request and this response, together with a statement of why you believe this initial determination is in error Also, if you appeal, you should clearly indicate on the envelope and in the letter that it is a "Freedom of Information Act Appeal"

Sincerely,


Elaine Newton
OGE FOIA Officer

Enclosures

United States
Office of Government Ethics
1201 New York Avenue, NW., Suite 500
Washington, DC 20005-3917

Jeremy Singer-Vine
Ken Bensinger
Buzzfeed

## Tracking No: OGE FOIA FY 15/01

Dear Mr. Singer-Vine and Mr. Bensinger:
This letter responds to your Freedom of Information Act (FOIA) request, which was received by the U.S. Office of Government Ethics (OGE) FOIA Office on October 14, 2014. In your request, you asked for copies of "all executive-branch public financial disclosure reports (SF 278 / OGE Form 278) and associated ethics agreements filed with the OGE since January 1, 2004." You also asked for "all related files (databases, spreadsheets, et cetera) related to these reports." On October 27, 2014, you clarified your request, noting that you want only those reports currently in a "digitized" form and that you wanted a list of 278 filers that is arranged by the same categories of information presently available on our automate system (e.g., filer name, agency, position, and filing season).

We are enclosing an excel spreadsheet that contains the filers' name, agency, position, and filing year for the requested reports. Please note that under 5 U.S.C. app. § 105 (d), OGE 278 reports are generally destroyed six years after receipt of the report or destroyed after one year in certain circumstances.

In regard to the public financial disclosure reports (OGE 278s), OGE 278s are not available under FOIA, pursuant to FOIA Exemption (b)(3), 5 U.S.C. § 552(b)(3) as material specifically exempted from disclosure by another statute. Access to the OGE 278 s is only available under the special access provision of the Ethics in Government Act of 1978 (5 U.S.C. appendix, § 105) and OGE's regulations. The special access provision requires an individual to submit a written application to access these reports that states his or her name, occupation and address; the name and address of any other person or organization on whose behalf the copy is requested; and that he or she is aware of the prohibitions on the obtaining or use of the report. As your request provided all of the required information, we are processing your request for OGE 278s under this special access provision. In addition, we will provide the ethics agreements associated with the requested OGE 278s through this process. Again, please note that under 5 U.S.C. app. § 105(d), OGE 278 reports are generally destroyed six years after receipt of the report or destroyed after one year in certain circumstances.

The OGE official responsible for this FOIA determination is the undersigned. In accordance with the FOIA, as codified at 5 U.S.C. § 552(a)(6)(A), and OGE's FOIA regulations, at 5 C.F.R. § 2604.304, you may administratively appeal this determination to the General

Counsel, U.S. Office of Government Ethics, 1201 New York Avenue, N.W., Suite 500, Washington, DC 20005-3917. Any such appeal must be in writing and must be sent within 30 days of the date you receive this response letter. If you do appeal, you should include copies of your request and this response, together with a statement of why you believe this initial determination is in error. Also, if you appeal, you should clearly indicate on the envelope and in the letter that it is a "Freedom of Information Act Appeal."




Hamburg, Margaret A
Hamburg, Margaret A

Hamburg, Margaret A

Hamburg, Margaret A


Department Of Health And Human Services
Department Of Health And Human Services
Department Of Health And Human
Services
Department Of Health And Human
Services
Department Of Health And Human
Services


Filer

Name
Hamburg, Margaret A
Agency/Position
Department Of Health And Human Services Commissioner Food and Drug Administration

| Workflow and Routing |  |  | need instructions? |
| :---: | :---: | :---: | :---: |
| Routing Step Number | Task Summary |  |  |
| of 5 |  |  |  |
| Review |  |  |  |
| Type |  | Processed by |  |
| Annual |  |  |  |
| Agency Contact |  | Agency Contact Email | Agency Contact Phone |
| Releasability |  | Status (Auto) | Received From |
| POST to OGE website |  | Certified | <select one> |
| DAEO? | Year | Extensions Filed | Termination Date |
|  | 2010 |  |  |



Dates \& Other
Reviewer Comments
Edit
Date Received
08/03/2010
Date Assigned
08/10/2010
Reviewer
Daniel L. Skalla

Review Start
08/12/2010
Initial Review
Complete
08/12/2010
Forward For
Certification
08/12/2010
Select Certifier

Returned To

| Reviewer |
| :--- |
| File Uncertified |
| Certified By |
| Date Certified |
| $03 / 07 / 2011$ |

## Computed status: Certified

Current User: Rachel K. Dowell

| Filer |  |  |  |
| :---: | :---: | :---: | :---: |
| Name | Agency/Position |  |  |
| Hamburg, Margaret A | Department Of Health And Human Services Commissioner Food and Drug Administration |  |  |
| Workflow and Routing |  |  | need instructions? |
| Routing Step Number | Task Summary |  |  |
| of 5 |  |  |  |
| Review |  |  |  |
| Type |  | Processed by |  |
| Annual |  |  |  |
| Agency Contact |  | Agency Contact Email | Agency Contact Phone |
| Releasability |  | Status (Auto) | Received From |
| POST to OGE website |  | Certified | <select one> |
| DAEO? | Year | Extensions Filed | Termination Date |
|  | 2011 |  |  |




| Reviewer |
| :--- |
| File Uncertified |
| Certified By |
| Date Certified |
| $03 / 28 / 2012$ |

Computed status: Certified
Current User: Rachel K. Dowell
Form 278 - Annual
Filer
Name
Hamburg, Margaret A
Workflow and Routing
Routing Step Number
of 5

| Add Support Doc |  |  |  |
| :---: | :---: | :---: | :---: |
| Support Documents |  |  |  |
| Date | Title | Status | Category |
| 2012 | ANNUAL - MARGARET=A-HAMBURG-2012FORM278CERTIFIED.PDF | Final | 2-278 |


| Dates \& Other | Reviewer Comments |
| :---: | :---: |
| Edit | open 278 Fileroom entries |
| Date Received |  |
| 09/13/2012 |  |
| Date Assigned |  |
| 09/25/2012 |  |
| Reviewer |  |
| Mark R.B. Stewart |  |
| Review Start |  |
| 10/25/2012 |  |
| Initial Review Complete |  |
| 10/25/2012 |  |
| Forward For Certification |  |
|  |  |
| Select Certifier |  |
| $\begin{aligned} & \text { Returned To } \\ & \text { mation-not part of record } \end{aligned}$ |  |


| Reviewer |
| :--- |
| File Uncertified |
| Certified By |
| Date Certified |
| $10 / 25 / 2012$ |

## Computed status: Certified

Current User: Rachel K. Dowell

## Filer

Name
Hamburg, Margaret A
Agency/Position
Department Of Health And Human Services Commissioner Food and Drug Administration

| Workflow and Routing |  |  | need instructions? |
| :---: | :---: | :---: | :---: |
| Routing Step Number | Task Summary |  |  |
| of 5 |  |  |  |
| Review |  |  |  |
| Type |  | Processed by |  |
| Annual |  |  |  |
| Agency Contact |  | Agency Contact Email | Agency Contact Phone |
| Releasability |  | Status (Auto) | Received From |
| POST to OGE website |  | Certified | <select one> |
| DAEO? | Year | Extensions Filed | Termination Date |
|  | 2013 |  |  |


| Reviewer |
| :--- |
| File Uncertified |
| Certified By |
| Date Certified |
| $09 / 27 / 2013$ |

## Computed status: Certified

Current User: Rachel K. Dowell
Form $278=$ Annual

Name
Hamburg, Margaret A

Agency/Position
Department Of Health And Human Services Commissioner Food and Drug Administration

| Workflow and Routing |  |  | need instructions? |
| :---: | :---: | :---: | :---: |
| Routing Step Number | Task Summary |  |  |
| of 5 |  |  |  |
| Review |  |  |  |
| Type |  | Processed by |  |
| Annual |  |  |  |
| Agency Contact |  | Agency Contact Email | Agency Contact Phone |
| Releasability |  | Status (Auto) | Received From |
| POST to OGE website |  | Certified | <select one> |
| DAEO? | Year | Extensions Filed | Termination Date |
|  | 2014 |  |  |

## Filer




File Uncertified

Certified By

Date Certified
11/18/2014

## Computed status: Certified

Current User: Rachel K. Dowell

## Filer

Name
Hamburg, Margaret A

Agency/Position
Department Of Health And Human Services Commissioner Food and Drug Administration

| Workflow and Routing |  |  | need instructions? |
| :---: | :---: | :---: | :---: |
| Routing Step Number | Task Summary |  |  |
| of 5 |  |  |  |
| Review |  |  |  |
| Type |  | Processed by |  |
| Annual Term |  |  |  |
| Agency Contact |  | Agency Contact Email | Agency Contact Phone |
| Releasability |  | Status (Auto) | Received From |
| POST to OGE website |  | Certified | <select one> |
| DAEO? | Year | Extensions Filed | Termination Date |
|  | 2015 | 45 Days |  |

Support Documents

| Date | Title | Status | Category |
| :--- | :--- | :--- | :--- | :--- |
| none | TERMINATION - MARGARET-A-HAMBURG-2015FORM278TERMINATION.PDF | Final | $\mathbf{2 - 2 7 8}$ |


| Dates \& Other | Reviewer Comments |
| :---: | :---: |
| Edit | open 278 Fileroom entries |
| Date Received |  |
| 07/16/2015 |  |
| Date Assigned |  |
| 07/16/2015 |  |
| Reviewer |  |
| Daniel L. Skalla |  |
| Review Start |  |
| 07/17/2015 |  |
| Initial Review Complete |  |
| 07/17/2015 |  |
| Forward For Certification |  |
| 07/17/2015 |  |
| Select Certifier |  |
| Returned To |  |

File Uncertified

Certified By
Emory Rounds
Date Certified
07/21/2015

Computed status: Certified
Current User: Rachel K. Dowell

## Financial Disclosure Tracking System

| Name of Filer: Hamburg , Margaret |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Report Type: Annual |  |  |  |  |  |  |  |
| Reporting Year: 2014 |  |  |  |  |  |  |  |
| Department/Agency: Department Of Health And Human Services |  |  |  |  |  |  |  |
|  | Commissioner Food and Drug Administration |  |  |  |  |  |  |
| DAEO: No |  |  |  |  |  |  |  |
| Original From Agency: 11/5/2014 |  |  |  |  |  |  |  |
| OGE 1st Extension Granted: No |  |  |  |  |  |  |  |
| OGE 2nd Extension Granted: No |  |  |  |  |  |  |  |
| Confirm/Entr: 5/18/2009 R |  |  | Recess Appointment: |  | Termination: |  |  |
| Revlewer: | Gu2man |  |  |  |  |  |  |
| To | 11/10/201 | Review | 11/18/201 | Review | 11/18/201 | Revlewer | 11/18/201 |
| Reviewer: | 4 | Started: | 4 | End: | 4 | Approved: | 4 |
| Recommen | ation: | (5) |  |  |  |  |  |

## Report Review Approvals

| OGE Official | Review Start | Date | Review Complete | Oate |
| :--- | :--- | :--- | :--- | :--- |
| OGE Director | - | - | - | - |

Comments of Reviewer

## (b)(5)

## (b)(5)



United States Office of Government Ethics
Financial Disclosure Tracking System
278 Review Sheet
11/18/2014


(b)(5)


United States Office of Government Ethics

## Financial Disclosure Tracking System



## Report Review Approvals

| OGE Official | Review Start | Date | Review Complete | Date |
| :--- | :--- | :--- | :--- | :--- |
| OGE Director | - | - | - | - |

## Comments of Reviewer


$\qquad$

United States Office of Government Ethics
Financial Disclosure Tracking System 278 Review Shee


## Michelle MaGee

## From:

Hall, Randall (HHS/OGC) [b(b)
Sent:
Thursday, September 26, 2013 10:26 AM
To:
Michelle MaGee
Subject:
RE: 278 Question

Michelle,


Let me know if you need additional information.

Randy

Randall J. Hall
Attorney-Advisor (Team Leader)
Financial Disclosure Section
Ethics Division
OGC, HHS
(b)(6)

From: Michelle MaGee [mailto:mmagee@oge,goy]
Sent: Thursday, September 26, 2013 10:04 AM
To: Hall, Randall (HHS/OGC)
Subject: 278 Question

Hi Mr. Hall,
I have a question regarding Margaret A. Hamburg's 278. In reviewing Mrs. Hamburg's financial disclosure form,
$\square]^{\text {(b)(5) }}$

Thank you,
Michelle MaGee
Program Analyst
U.S. Office of Government Ethics

1201 New York, Ave, NW
Suite 500
Washington, DC 20005
Tel: 202-482-9245

## Financial Disclosure Tracking System <br> SF278 Review Sheet




## Financial Disclosure Tracking System

SF278 Review Sheet

## Comments of 2nd Level:(b)

Other Comment:

Comments of Signing Official:

## Financial Disclosure Tracking System

SF278 Review Sheet

| Name of Filer: HAMBURG. MARGARET A. |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Report Type: Annual |  |  |  |  |  |  |  |
| Reporting Year: 2011 |  |  |  |  |  |  |  |
| Department/Agency: DEPARTMENT OF HEALTH AND HUMAN SERVICES |  |  |  |  |  |  |  |
| Position: DEPARTMENT OF HEALTH AND HUMAN SERVICES |  |  |  |  |  |  |  |
| DAEO: No |  |  |  |  |  |  |  |
| Job Status: Full Time |  |  |  |  |  |  |  |
| Original From Agency: 9/22/2011 |  |  |  |  |  |  |  |
| OGE Extension Granted: |  |  |  |  |  |  |  |
| Confirm/Entr: | : 5/18/2009 | Recess Appointment: |  |  | Termination: |  |  |
| Reviewer: BJKHANF:R |  |  |  |  |  |  |  |
| To Reviewer: | 1/19/2012 | Review Started: | 1/20/2012 | Review <br> End: | 1/20/2012 | Reviewer Approved: | 1/20/2012 |
| Recommendation: (b)(5) |  |  |  |  |  |  |  |

Report Review Approvals

## OGE Official

Review Start

## Date

Review Complete
Date
Second Level Rvw
Chief, fol) $\qquad$


OGE Director $\qquad$
$\qquad$
$\qquad$
Comments of Reviewer:
(b)(5)


Financial Disclosure Tracking System
SF278 Review Sheet


Financial Disclosure Tracking System
SF278 Review Sheet


4 pages of reviewer's notes redacted in full (b)(5)

## Lorna Syme - RE: Responses re: Dr. Hamburg's Holdings

```
From: "Swindell, Edgar M. (HHS/OGC)" \(\langle(b)(6)\)
```



```
        Fischmann" <ejfischm@oge.gov>, "Lorna Syme" <lasyme@oge.gov>
Date: \(02 / 26 / 2009\) 3:5I PM
Subject: RE: Responses re: Dr. Hamburg's Holdings
```

Walter,
Ask about the two holding ${ }^{(b)(6)}$

Ed


From: Walter Shaub [mailto:wmshaub@oge.gov]
Sent: Thursday, February 26, 2009 3:45 PM
To: Swindell, Edgar M. (HHS/OGC); Hall, Randall (HHS/OGC); Elizabeth Fischmann; Lorna Syme Subject: Fwd: Responses re: Dr. Hamburg's Holdings

```
>>> "Buchwald, Michael" .(b)(6) > 2/25/2009 2:14 PM >>>
```

Walt,

We are getting back to you on the following 4 items re: Dr. Hamburg's
holdings:


Here is the additional information we would like to provide on each remaining issue:

(b)(6)


Please let us know if you have any questions.
Thanks very much.
Sincerely,
Mike Buchwald
Michael F. Buchwald
O'Melveny \& Myers L $\llcorner\mathrm{P}$


This message and any attached documents contain information from the law firm of O'Melveny \& Myers LLP that may be confidential and/or privileged. If you are not the intended recipient, you may not read, copy, distribute, or use this information. If you have received this transmission in error, please notify the sender immediately by reply e -mail and then delete this message.

11 pages of reviewer's notes redacted in full (b)(5)

Mr. Edgar M. Swindell

Associate General Counsel/Ethics
Designated Agency Ethics Official
U.S. Department of Health and Human Services

Room 710-E, Hubert H. Humphrey Building
200 Independence Avenue, SW
Washington, DC 20201
Dear Mr. Swindell:
The purpose of this letter is to describe the steps that I will take to avoid any actual or apparent conflict of interest in the event that I am confirmed for the position of Commissioner, Food and Drug Administration, U.S. Department of Heath and Human Services.

As required by 18 U.S.C. § 208(a), I will not participate personally and substantially in any particular matter that has a direct and predictable effect on my financial interests or those of any person whose interests are imputed to me, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1), or qualify for a regulatory exemption, pursuant to 18 U.S.C. § 208(b)(2). I understand that the interests of the following persons are imputed to me: any spouse or minor child of mine; any general partner of a partnership in which I am a limited or general partner; any organization in which I serve as officer, director, trustec, general partner or employee; and any person or organization with which I am negotiating or have an arrangement conceming prospective employment.

Upon confirmation, I will resign from the following positions reported in my financial disclosure report:

```
The Rockefeller Foundation (Board of Trustees)
Aaron Diamond AIDS Research Center (Board of Directors)
Drug Strategies (Board of Directors)
Trust for America's Health (Board of Directors)
Institute of Medicine Council
Math for America (Board of Directors)
National Health Museum (Board of Directors)
Conservation International (Board of Directors)
Sidwell Friends School (Board of Trustees)
March of Dimes (Public Policy Advisory Council)
The Project on Emerging Nanotechnologies, Woodrow Wilson International Center for
    Scholars (Board Member)
Journal of Biosecurity and Bioterrorism (Editorial Board)
Institute of Medicine, National Academy of Science (Chair, Board on Global Health)
Institute of Medicine, Forum on Microbial Threats (Vice-Chair)
```

Mr. Edgar M. Swindell

Page 2

## Nuclear Threat Initiative (Senior Scientist)

In addition, I resigned from the Board of Directors of Doctors of the World in August 2008; from the Board of Trustees of Rockefeller University in November 2008; and from my position at the American Society for Microbiology in July 2008. For a period of one year after my resignation from each of these entities, I will not participate personally and substantially in any particular matter involving specific partics in which that entity is a party or represents a party, unless I am first authorized to participate, pursuant to 5 C.F.R. § 2635.502(d).

Within the past year, I have provided services to the Markle Foundation, the Heinz Foundation, the deBeaumont Foundation, and the Irene Diamond Foundation. For a period of one year after I last provided services to each of these entities, I will not participate personally and substantially in any particular matter involving specific parties in which that entity is a party or represents a party, unless I am first authorized to participate, pursuant to 5 C.F.R. § 2635.502(d).

Following my appointment, my spouse and I will divest our interests in the following entities within 90 days of my confirmation:

Renaissance Institutional Equities Fund RMP LLP
Renaissance Institutional Futures Fund RMP
Solera Executive Partners LP
Topspin Partners LBO
With regard to each of these entities, I will not participate personally and substantially in any particular matter that has a direct and predictable effect on the financial interests of the entity until I have divested it, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1), or qualify for a regulatory exemption, pursuant to 18 U.S.C. § 208(b)(2).

Upon confirmation, I will resign from my positions on the Board of Directors and the Medical Advisory Board of Henry Schein, Inc. I currently hold stock, vested stock options, unvested stock options, and restricted stock in Henry Schein, Inc. I also participate in a Henry Schein, Inc., deferred compensation plan for Non-Employee Directors, pursuant to which I receive my compensation for serving as a Director as phantom stock. Under that plan, I am entitled to receive a distribution of Henry Schein stock equal to the value of my phantom stock upon my resignation from the Board of Directors. Upon my resignation from my positions with Henry Schein, Inc., I will forfeit any stock options and restricted stock that are unvested at the time of my resignation. Before I assume the duties of the position of Commissioner, Henry Schein, Inc., will pay all outstanding deferred compensation to me. Following my appointment, I will divest my vested stock options and stock in Henry Schein, Inc., by exercising all such options and divesting all stock within 90 days of my confirmation. I will not participate personally and substantially in any particular matter that has a direct and predictable effect on the financial interests of Henry Schein, Inc., until I have divested it, unless I first obtain a written

## Mr. Edgar M. Swindell

Page 3
waiver, pursuant to 18 U.S.C. § 208(b)(1), or qualify for a regulatory exemption, pursuant to 18 U.S.C. § 208(b)(2). For a period of one year after my resignation, I also will not participate personally and substantially in any particular matter involving specific partics in which Henry Schein, Inc., is a party or represents a party, unless I am first authorized to participate, pursuant to 5 C.F.R. § 2635.502(d).

Additionally, my spouse, my minor children, and I will divest our interests in Meritage Holdings LTD Class A and Meritage Investors LLC on or before July 1, 2009. I will not participate personally and substantially in any particular matter that has a direct and predictable effect on the financial interests of Meritage Investors LLC or Meritage Holdings LTD Class A of which I have knowledge until I have divested them, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1), or qualify for a regulatory exemption, pursuant to 18 U.S.C. § 208(b)(2).

My spouse owns a $25 \%$ share of Rockland Farm LLC, a family farm. The farm's grazing rights are currently leased and Rockland Farm LLC derives income from the rent paid for the lease. I do not hold a position with this entity. Through my spouse, 1 will continue to hold a financial interest in this entity, but I will not manage it or provide any other services to it. I will not participate personally and substantially in any particular matter that has a direct and predictable effect on the financial interests of Rockland Farm LLC, unless I first obtain a written waiver pursuant to 18 U.S.C. § 208(b)(1). Additionally, 1 will not participate personally and substantially in any particular matter that has a direct and predictable effect on the ability or willingness of the lease holders of the farm held by Rockland Farm LLC, to make rent payments, unless I first obtain a written waiver pursuant to 18 U.S.C. § 208(b)(1).

My spouse is an employee of Renaissance Technologies Corporation ("RTC"), and we have investments in that entity and certain funds it manages. The terms of our investments are such that I do not know the underlying assets of the funds. My spouse is contractually prohibited from disclosing any of the holdings of specific funds managed by RTC to anyone (except as disclosures are required to be made in the ordinary course of the funds' business), including to any family member. As Commissioner, I will not participate personally and substantially in any particular matter in which I know that at the time of my participation I, through my family's interest in RTC, have a financial interest, if that particular matter will have a direct and predictable effect on any such interest, unless I first obtain a written waiver, pursuant to 18 U.S.C. § 208(b)(1), or qualify for a regulatory exemption, pursuant to 18 U.S.C. § 208(b)(2).

In order to avoid potential conflicts of interest during my appointment as Commissioner, I, my spouse, or any minor children of mine will not acquire any direct financial interest in entities listed on the FDA prohibited holdings list or in entities involved, directly or through subsidiaries, in the following industries: (1) research, development, manufacture, distribution, or sale of pharmaceutical, biotechnology, or medical devices, equipment, preparations, treatment, or products; (2) veterinary products; (3) healthcare management or delivery; (4) health, disability, or workers compensation insurance or related services; (5) food and/or beverage

Mr. Edgar M. Swindell<br>Page 4

production, processing or distribution; (6) communications media; (7) computer hardware, computer software, and related internet technologies; (8) wireless communications; (9) social sciences and economic research organizations; (10) commercial airlines, railroads, shiplines, and cargo carriers; or (11) sector mutual funds that concentrate their portfolios on one country other than the United States. In addition, we will not acquire any direct financial interests in sector mutual funds that concentrate in any of these sectors.

Sincerely,


DATE LOG OF
APPLICATIONS FOR COPIES OF RF 278


NOTE:
This log sheet will be placed on the inside back cover of the 278 file folders and will be uses to (1) record the date on which an application (OGE form 201) was made to receive/inspect copies of 8 FF 278 's; and (2) provide a date reference to the 201 file to locate copies of the 201 when such a request is received to see the 201.

1 page redacted in full (b)(5)

| From: | 278Tracking |
| :--- | :--- |
| Sent: | Monday, November 10, 2014 11:30 AM |
| To: | 'Hall, Randall (HHS/OGQ); 278Tracking |
| Cc: | Ciara M. Guzman; Michelle MaGee; Jaideep Mathai; David A. Meyers; Daniel L. Skalla; |
|  | Michelle M. Walker |
| Subject: | RE: CY 2013 OGE 278s |

Greetings!

We received the Public Financial Disclosure reports for:

- Francis S. Collins - Annual CY 2013-OGE Reviewer: CIARA GUZMAN

LT Margaret A. Hamburg - Annual CY 2013 - OGE Reviewer: CIARA GUZMAN

- Pamela S. Hyde - Annual CY 2013 - OGE Reviewer: MICHELLE MAGEE
- Nicole Luri - Annual CY 2013 - OGE Reviewer: JAIDEEP MATHAI
- Kathleen G. Sebelius- Annual/Term (Date: 6/13/2014) - OGE Reviewer: DAVID NaIMERS
- Howard Koh - Annual/Term (Date: 6/13/2014) - OGE Reviewer: DANIEL SKALLA
- Marilyn B. Tavenner - Annual CY 2013 - OGE Reviewer: MICHELLE WALKER

The assigned OGE Reviewer will contact you if there are questions.
Best regard,
U.S. Office of Government Ethics

Compliance Division
1201 New York Ave., NW, Suite 500
Washington, DC 20005-3917
Tel. 202.482.9278

Visit OGE's website: wnw.oge.gov
Follow OGE on Twitter: @OfficeGovEthics

From: Hall, Randall (HHS/OGC) (b)(6)
Sent: Wednesday, November 05, 2014 2:58 PM
To: 278Tracking
Cc: Lori Kelly
Subject: CY 2013 OGE 278s

Enclosed is HHS' second submission in 2014 for the CY2013 reports of PAS appointees and for the DAEO. If you have any questions please contact me.

Randall J. Hall
Attorney-Advisor (Team Leader)
Financial Disclosure Section
Ethics Division
HHS, OGC
(b)(6)

26 pages of personal financial information redacted in full (b)(6)
1 page of reviewer's notes redacted in full (b)(5)

## Veda E. Marshall

| From: | Hall, Randall (HHS/OGC) [(b)(6) |
| :--- | :--- |
| Sent: | Thursday, September 19, 2013 10:05 AM |
| To: | 278Tracking |
| Cc: | Patricia C. Zemple; Kim, Theodore (OS/OGC) |
| Subject: | OGE 278s |
| Attachments: | OGEFowardingLetter2013(2).pdf; OGE278BenjaminTerm.pdf; |
|  | OGE278BenjaminCY2012.pdf; OGE278HamburgCY2012.pdf; OGE278MurrayCY2012.pdf |

Enclosed is HHS' second submission in 2013 for the CY2012 reports of PAS appointees. If you have any questions please contact me.

Randall J. Hall
Attorney-Advisor (Team Leader)
Financial Disclosure Section
Ethics Division
HHS, OGC
(b)(6)

United States
Office of Government Ethics
1201 New York Avenue, NW., Suite 500
Washington, DC 20005-3917

July 2, 2009
Edgar Swindell
Associate General Counsel
Department of Health and Human Services
700-E Humphrey Building
200 Independence Avenue, Sw.
washington, DC 20201
Dear Mr. Swindell:
This letter concerns ethics agreements made by presidential appointees to positions requiring the advice and consent of the Senate, pursuant to 5 U.S.C. App. 110. Upon confirmation, an appointee has 90 days (unless otherwise specified by the agreement) in which to satisfy any ethics agreement.

An appointee must notify her designated agency ethics official (DAEO) of any action (s) taken to satisfy her ethics agreement. Once the DAEO has received verification of compliance, he must submit this documentation to the Office of Government Ethics (OGE) and the appropriate Senate confirmation committee. (See 5 C.F.R. 2634.804.)

To assist agencies in ensuring that appointees comply with their ethics agreements within 90 days, $I$ am writing to remind you that the following appointee has made an ethics agreement. As of July 2, 2009, she has 45 days remaining to comply with her ethics agreement.
$\frac{\text { Appointee }}{\text { Hamburg, Margaret }} \quad \frac{\text { Confirmation Date }}{\text { May } 18,2009} \quad \frac{\text { Compliance Expiration Date }}{\text { AUGUST 16, } 2009}$

If she has already complied, please collect the documentation and forward it to OGE. Should you have any questions or require additional assistance, such as obtaining a Certificate of Divestiture for an appointee, please do not hesitate to contact me at 202-282-9309 or khkaplan@oge.gov.

Sincerely,


Kim Kaplan
Government Ethics Specialist

United States
Office of Government Ethics
1201 New York Avenue, NW., Suite 500
Washington, DC 20005-3917

April 17, 2009

Margaret A. Hamburg
10903 New Hampshire Avenue
Silver Springs, MD 20903
Dear Dr. Hamburg:
Congratulations on your nomination to the position of Commissioner, Food and Drug Administration. I hope you will find the position both challenging and rewarding.

Enclosed for your information is a copy of the letter sent to the U.S. Senate stating that the Office of Government Ethics has reviewed your financial disclosure report and that you are in compliance with applicable laws and regulations governing conflicts of interest. Also enclosed is a pamphlet entitled "Ethics Starts Here: A Guide for Senior Officials" to provide you with an introduction to the Government ethics rules. We hope you will find this overview helpful.

As you may already know, all Federal agencies have a Designated Agency Ethics Official (DAEO). If, in the course of the confirmation process, you have any questions about conflicts of interest or other ethics related matters, you should contact your DAEO, Edger Swindell, or a member of his ethics staff.

I wish you all the best as you proceed through the confirmation process.


Enclosures

2 pages withheld entirely under (b)(5)

Preventing Conflicts of Interest in the Executive Branch

## Resolved Interactions Details

## Reopen Interaction

## Title:

Press call for a Financial disclosure report
Interaction \#: 8516
Status: Resolved

## Customer Information

Source: Press
First Name: Katie
Last Name: Watson
Title: Reporter

## Interaction Details

Initiated: 4/1/2016
Call Origination: Phone
Assigned: Seth Jaffe
Watching:

## Questions

This is Katie Watson, reporter for the Daily Caller News Foundation. I left a voice message earlier, but I need to obtain the financial disclosure forms for former FDA Commissioner Dr. Margaret Hamburg, for her entire tenure as FDA commissioner. Ideally, I would like to get that today, but Monday would be alright as well. I'm happy to pick them up in person and pay for any necessary copying fees.

## Category(s)

## 278s

## Interaction History

4/1/2016: Resolved
Seth Jaffe
I directed the caller to the appropriate place on OGE's website to fill out an automated Form 201 to request public financial disclosure reports.

4/1/2016: Interaction Created
Seth Jaffe

## Resolution Details

Interaction Resolved:4/1/2016
Resolution Category:Resolved
Response:
I directed the caller to the appropriate place on OGE's website to fill out an automated Form 201 to request public financial disclosure reports.

## Complexity:(b)

Amount Of Time Spent On Interaction:0-1 hour Individuals Credited:Seth Jaffe
Add To Agency Profile: No
Memorialize Content: No
Do Not Destroy: No

